These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 21194571)

  • 21. Effects of Na+ channel blockers on the restitution of refractory period, conduction time, and excitation wavelength in perfused guinea-pig heart.
    Osadchii OE
    PLoS One; 2017; 12(2):e0172683. PubMed ID: 28231318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency-dependent antiarrhythmic drug effects on postrepolarization refractoriness and ventricular conduction time in canine ventricular myocardium in vivo.
    Costard-Jäckle A; Franz MR
    J Pharmacol Exp Ther; 1989 Oct; 251(1):39-46. PubMed ID: 2795468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequency-independent blockade of cardiac Na+ channels by riluzole: comparison with established anticonvulsants and class I anti-arrhythmics.
    Mestre M; Djellas Y; Carriot T; Cavero I
    Fundam Clin Pharmacol; 2000; 14(2):107-17. PubMed ID: 10796057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs.
    Desaphy JF; Carbonara R; Costanza T; Conte Camerino D
    Exp Neurol; 2014 May; 255(100):96-102. PubMed ID: 24613829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Estimation of depressant effects of class I antiarrhythmic drugs on intraventricular conduction--rate-dependent effects on QRS duration].
    Ikeda N; Kamiya K
    Jpn Circ J; 1992; 56 Suppl 5():1477-9. PubMed ID: 1337924
    [No Abstract]   [Full Text] [Related]  

  • 26. Electrophysiologic effects of sodium channel blockade on anisotropic conduction and conduction block in canine myocardium: preferential slowing of longitudinal conduction by flecainide versus disopyramide or lidocaine.
    Kondo T; Yamaki M; Kubota I; Tachibana H; Tomoike H
    J Am Coll Cardiol; 1997 Jun; 29(7):1639-44. PubMed ID: 9180130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations in cardiac sodium channels: clinical implications.
    Liu H; Clancy C; Cormier J; Kass R
    Am J Pharmacogenomics; 2003; 3(3):173-9. PubMed ID: 12814325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation.
    Windle JR; Geletka RC; Moss AJ; Zareba W; Atkins DL
    Ann Noninvasive Electrocardiol; 2001 Apr; 6(2):153-8. PubMed ID: 11333173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atrial selectivity in Na+channel blockade by acute amiodarone.
    Suzuki T; Morishima M; Kato S; Ueda N; Honjo H; Kamiya K
    Cardiovasc Res; 2013 Apr; 98(1):136-44. PubMed ID: 23341577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolongation of the QT interval by dofetilide modulates rate-dependent effects of mexiletine on intraventricular conduction.
    Todt H; Zojer N; Raberger G; Schütz W
    Eur J Pharmacol; 1994 Nov; 265(1-2):43-52. PubMed ID: 7883028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of flecainide induced negative inotropy: An in silico study.
    Yang PC; Giles WR; Belardinelli L; Clancy CE
    J Mol Cell Cardiol; 2021 Sep; 158():26-37. PubMed ID: 34004185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting QRS and PR interval prolongations in humans using nonclinical data.
    Bergenholm L; Parkinson J; Mettetal J; Evans ND; Chappell MJ; Collins T
    Br J Pharmacol; 2017 Oct; 174(19):3268-3283. PubMed ID: 28675424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of an antiarrhythmic drug A-2545 on canine ventricular arrhythmia models; comparison with mexiletine and flecainide.
    Xue YX; Arita J; Aye NN; Hashimoto K
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Dec; 358(6):649-56. PubMed ID: 9879724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome.
    Wolpert C; Echternach C; Veltmann C; Antzelevitch C; Thomas GP; Spehl S; Streitner F; Kuschyk J; Schimpf R; Haase KK; Borggrefe M
    Heart Rhythm; 2005 Mar; 2(3):254-60. PubMed ID: 15851314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The comparative sensitivity of three in vitro safety pharmacology models for the detection of lidocaine-induced cardiac effects.
    Goineau S; Castagné V; Guillaume P; Froget G
    J Pharmacol Toxicol Methods; 2012 Jul; 66(1):52-8. PubMed ID: 22691624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Probing flecainide block of I
    Geng L; Kong CW; Wong AOT; Shum AM; Chow MZY; Che H; Zhang C; Yau KL; Chan CW; Keung W; Li RA
    Toxicol Lett; 2018 Sep; 294():61-72. PubMed ID: 29758359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Upregulation of the rat cardiac sodium channel by in vivo treatment with a class I antiarrhythmic drug.
    Taouis M; Sheldon RS; Duff HJ
    J Clin Invest; 1991 Aug; 88(2):375-8. PubMed ID: 1650791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cutaneous analgesic effect of class I antiarrhythmic drugs.
    Tzeng JI; Cheng KI; Huang KL; Chen YW; Chu KS; Chu CC; Wang JJ
    Anesth Analg; 2007 Apr; 104(4):955-8. PubMed ID: 17377113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. QTc shortening with a new investigational cancer drug: a brief case study.
    Himmel HM; Hoffmann M
    J Pharmacol Toxicol Methods; 2010; 62(1):72-81. PubMed ID: 20570746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How to determine cardiac ion channels targeted by drugs using the isolated rabbit ventricular wedge model.
    Liu G; Liu T; Cohen D; Liu T; Yan GX
    J Pharmacol Toxicol Methods; 2016; 81():161-70. PubMed ID: 27195944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.